S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Watch for your Federal QR code (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Watch for your Federal QR code (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Watch for your Federal QR code (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Watch for your Federal QR code (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Watch for your Federal QR code (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Watch for your Federal QR code (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Watch for your Federal QR code (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Watch for your Federal QR code (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Watch for your Federal QR code (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Watch for your Federal QR code (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Watch for your Federal QR code (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Watch for your Federal QR code (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
NASDAQ:IDXX

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

$576.29
+4.98 (+0.87%)
(As of 02/23/2024 ET)
Today's Range
$568.76
$577.52
50-Day Range
$515.08
$576.29
52-Week Range
$372.50
$579.68
Volume
256,622 shs
Average Volume
432,795 shs
Market Capitalization
$47.89 billion
P/E Ratio
57.23
Dividend Yield
N/A
Price Target
$591.50

IDEXX Laboratories MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
2.6% Upside
$591.50 Price Target
Short Interest
Healthy
2.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.09
Upright™ Environmental Score
News Sentiment
0.92mentions of IDEXX Laboratories in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$34.60 M Sold Last Quarter
Proj. Earnings Growth
14.73%
From $11.13 to $12.77 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.40 out of 5 stars

Medical Sector

116th out of 936 stocks

Diagnostic Substances Industry

3rd out of 13 stocks


IDXX stock logo

About IDEXX Laboratories Stock (NASDAQ:IDXX)

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDXX Stock Price History

IDXX Stock News Headlines

Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
IDXX Jun 2024 640.000 call
Gold is SOARING – here's what you need to do
Everything is lining up perfectly for a historic gold bull run. One gold expert says he's found the best way to get in, for just $5.
IDXX Feb 2024 550.000 call
IDEXX Laboratories Inc Insider Sells Shares
Q4 2023 IDEXX Laboratories Inc Earnings Call
IDEXX Laboratories Shares Rise On Upbeat Q4 Results
See More Headlines
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/05/2024
Today
2/25/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
10,780
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$591.50
High Stock Price Target
$655.00
Low Stock Price Target
$460.00
Potential Upside/Downside
+2.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$845.04 million
Pretax Margin
28.99%

Debt

Sales & Book Value

Annual Sales
$3.66 billion
Cash Flow
$10.91 per share
Book Value
$17.86 per share

Miscellaneous

Free Float
81,347,000
Market Cap
$47.89 billion
Optionable
Optionable
Beta
1.25

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Should I Buy IDEXX Laboratories Stock? IDXX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of IDEXX Laboratories was last updated on Tuesday, February 20, 2024 at 10:35 PM.

Pros

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

  • Recent increase in stock value, showing potential for growth.
  • Strong presence in companion animal veterinary market, providing stable revenue streams.
  • Diversified product portfolio catering to various markets like livestock, poultry, and water testing.
  • Ongoing development of innovative diagnostic products, ensuring competitiveness in the industry.
  • Consistent financial performance and revenue growth over the past quarters.

Cons

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

  • Dependency on the veterinary and livestock markets, susceptible to fluctuations in these industries.
  • Competitive landscape with other diagnostic companies, potentially impacting market share.
  • Regulatory challenges in the healthcare equipment industry affecting product development and sales.
  • Market volatility and economic uncertainties impacting investor confidence.
  • Potential impact of global events like pandemics on demand for diagnostic products.














IDXX Stock Analysis - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IDXX shares.
View IDXX analyst ratings
or view top-rated stocks.

What is IDEXX Laboratories' stock price target for 2024?

9 brokerages have issued 12 month target prices for IDEXX Laboratories' stock. Their IDXX share price targets range from $460.00 to $655.00. On average, they predict the company's share price to reach $591.50 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price.
View analysts price targets for IDXX
or view top-rated stocks among Wall Street analysts.

How have IDXX shares performed in 2024?

IDEXX Laboratories' stock was trading at $555.05 at the start of the year. Since then, IDXX stock has increased by 3.8% and is now trading at $576.29.
View the best growth stocks for 2024 here
.

Are investors shorting IDEXX Laboratories?

IDEXX Laboratories saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 1,850,000 shares, an increase of 6.3% from the January 15th total of 1,740,000 shares. Based on an average daily trading volume, of 492,400 shares, the days-to-cover ratio is currently 3.8 days. Currently, 2.3% of the company's stock are short sold.
View IDEXX Laboratories' Short Interest
.

When is IDEXX Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our IDXX earnings forecast
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings results on Monday, February, 5th. The company reported $2.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.20. The firm had revenue of $901.60 million for the quarter, compared to analysts' expectations of $891.88 million. IDEXX Laboratories had a trailing twelve-month return on equity of 71.66% and a net margin of 23.08%. IDEXX Laboratories's revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the prior year, the firm posted $2.05 earnings per share.
Read the conference call transcript
.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories updated its FY 2024 earnings guidance on Monday, February, 5th. The company provided earnings per share guidance of 10.840-11.330 for the period, compared to the consensus EPS estimate of 11.000. The company issued revenue guidance of $3.9 billion-$4.0 billion, compared to the consensus revenue estimate of $4.0 billion.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.08%), Franklin Resources Inc. (1.69%), Brown Advisory Inc. (1.39%), Capital World Investors (1.23%), Norges Bank (1.11%) and Northern Trust Corp (1.04%). Insiders that own company stock include Brian P Mckeon, Daniel M Junius, George Fennell, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt and Sophie V Vandebroek.
View institutional ownership trends
.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IDXX) was last updated on 2/25/2024 by MarketBeat.com Staff